富士製薬工業(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証PRM | 医薬品 | 4554/E00975 | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2022/09/09 | 日証協 | 87,200株 | +22.24% | 35,300株 | +315.29% | 338,525株 | +0.68% | 51,305株 | +100.4% |
| 2022/09/02 | 日証協 | 71,334株 | -2.73% | 8,500株 | +70% | 336,229株 | +2.96% | 25,601株 | +139.15% |
| 2022/08/26 | 日証協 | 73,339株 | -12.18% | 5,000株 | +61.29% | 326,548株 | -0.49% | 10,705株 | +22.09% |
| 2022/08/19 | 日証協 | 83,514株 | -5.76% | 3,100株 | -80.38% | 328,150株 | -0.55% | 8,768株 | -74.51% |
| 2022/08/12 | 日証協 | 88,614株 | -6.04% | 15,800株 | -52.47% | 329,950株 | -1.9% | 34,400株 | -23.21% |
| 2022/08/05 | 日証協 | 94,314株 | +20.03% | 33,239株 | +32.93% | 336,350株 | +0.08% | 44,800株 | +57.77% |
| 2022/07/29 | 日証協 | 78,575株 | +13.1% | 25,005株 | +98.45% | 336,096株 | +2.91% | 28,395株 | -21.97% |
| 2022/07/22 | 日証協 | 69,475株 | +7.92% | 12,600株 | +320% | 326,595株 | -1.71% | 36,392株 | -27.34% |
| 2022/07/15 | 日証協 | 64,375株 | -21.51% | 3,000株 | -26.83% | 332,289株 | -4.84% | 50,085株 | -8.74% |
| 2022/07/08 | 日証協 | 82,014株 | +10.21% | 4,100株 | -34.92% | 349,189株 | +4.36% | 54,880株 | -21.01% |
| 2022/07/01 | 日証協 | 74,414株 | -2.36% | 6,300株 | +350% | 334,589株 | -0.21% | 69,481株 | +87.33% |
| 2022/06/24 | 日証協 | 76,214株 | -4.27% | 1,400株 | -92.93% | 335,288株 | -1.12% | 37,090株 | -40.06% |
| 2022/06/17 | 日証協 | 79,614株 | +4.74% | 19,800株 | +235.59% | 339,088株 | -1.8% | 61,880株 | +8.56% |
| 2022/06/10 | 日証協 | 76,014株 | +5.26% | 5,900株 | -69.07% | 345,298株 | +0.82% | 57,000株 | -3.35% |
| 2022/06/03 | 日証協 | 72,214株 | -27.65% | 19,077株 | -46.17% | 342,497株 | -3.08% | 58,978株 | -17.97% |
| 2022/05/27 | 日証協 | 99,814株 | +31.9% | 35,439株 | +190.48% | 353,397株 | +5.3% | 71,902株 | +66.42% |
| 2022/05/20 | 日証協 | 75,675株 | +12.49% | 12,200株 | -3.17% | 335,595株 | +1.24% | 43,204株 | -25.77% |
| 2022/05/13 | 日証協 | 67,275株 | +13.31% | 12,600株 | +740% | 331,491株 | 0% | 58,201株 | +3133.39% |
| 2022/05/06 | 日証協 | 59,375株 | -9.59% | 1,500株 | -31.19% | 331,491株 | -0.81% | 1,800株 | -94.77% |
※株式分割は考慮していませんのでご注意ください。
Page Top